ArticleSleep & breathing = Schlaf & Atmung2026
Predicting the Apnea-Hypopnea index for the diagnosis of obstructive sleep apnea with cardiovascular and cancer comorbidity using wearable sleep-tracking devices.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionObstructive Sleep Apnea (OSA) is a highly prevelance sleep breathing disorder that imposes, significant public health and economic burdens through its untreated associated comorbidities. The gold standard for diagnosing OSA, polysomnography (PSG), retains several limitations because it is cumbersome to conduct in the sleep lab and requires labor-intensive efforts to annotate the measurement. Furthermore, current research focuses on the alternative of PSG on the general OSA population without specifically considering the OSA comorbid conditions, such as cardiovascular and cancer diseases. There is a need for methods to monitor OSA using features derived from consumer sleep technologies (CSTs), considering comorbid conditions associated with OSA. METHODOLOGY: In this paper, we identify the features that can be collected from CSTs to predict the patient's Apnea-Hypopnea Index (AHI) with the consideration of the comorbid chronic diseases, including cardiovascular disease and cancer. These sleep characteristics include the total recording time, the sleep period time, total sleep time, the onset of sleep, the efficiency of sleep, the wakefulness after the onset of sleep, the percentages of N1, N2, N3, REM sleep stages, the latency of REM from sleep onset and the latency of REM from lights off.
resultsBased on these features, we build stepwise regression, LASSO, and XGBoost models to evaluate the risk of a patient having OSA and classify individuals as normal versus OSA, achieving classification accuracies of 68.76%, 69.26%, and 70.4%, respectively. The proposed method has been validated based on the Wisconsin Sleep Cohort Database. To test the generalization of the method, the model was validated on the IRB-approved Sanford Obstructive Sleep Apnea Cancer dataset. XGBoost demonstrated superior performance with the highest Recall (0.9136) and F1 Score (0.7647), while regression and Lasso excel in interpreting the features with the Precision (0.865).
conclusionSuch performance highlights their effectiveness in identifying OSA cases with comorbidity. Our proposed solutions introduce better interpretability of algorithms and improve the accuracy of OSA detection using CSTs while addressing the limitations of PSG.
Indexed as
Identifiers
41653357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.